The United States hasn’t yet been able to reap the cost savings seen in Europe – for a host of reasons.
From the Journals
But no effects on slowing spine or sacroiliac joint progression were seen in eight studies of NSAIDs and in one study of secukinumab.
ATLANTA – Just 1.2% of patients taking biologics with negative tuberculosis test results converted to positive results in annual tuberculosis...
News from the FDA/CDC
This is the fourth biosimilar for this tumor necrosis factor inhibitor to receive FDA approval.
Findings from the
ATLANTA – Certolizumab pegol shows multiple benefits – and improved benefit with earlier treatment – for axial spondyloarthritis.
ATLANTA – The selective JAK1 inhibitor upadacitinib had a rapid effect, with a clear difference emerging between the treatment and placebo groups...
MADRID – Systemic corticosteroid use and BMI impact risk of serious adverse events with certolizumab.
“This study was narrow in nature and we certainly need more information on the safety of Zostavax with patients on biologics with other mechanisms...
There appears to be very little to favor either ixekizumab or secukinumab over the other.
ATLANTA – Adding ixekizumab to conventional background medications significantly improved the signs and symptoms of nonradiographic axSpA in the...